Interferon [Beta]-1a and Atorvastatin in the Treatment of Multiple Sclerosis
This paper aims to evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled clinical trial. Multiple sclerosis patients were randomized independently, in a double blind design, into one of two treatment groups. Contr...
Gespeichert in:
| Veröffentlicht in: | Iranian journal of immunology 2016-03, Vol.13 (1), p.16 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 16 |
| container_title | Iranian journal of immunology |
| container_volume | 13 |
| creator | Ghasami, Keyvan Faraji, Fardin Fazeli, Masoud Ghazavi, Ali Mosayebi, Ghasem |
| description | This paper aims to evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled clinical trial. Multiple sclerosis patients were randomized independently, in a double blind design, into one of two treatment groups. Control group (n=45) received 30 μg/week interferon β-1a via intra-muscular injection. Atorvastatin-treated group (n=50) received interferon β-1a similar to control group in addition to atorvastatin (40 mg/day) for 18-months. All clinical and immunological variables were measured at the baseline and at the end of the study. There was no significant difference between the two groups in the expanded disability status scale scores and the number of gadolinium-enhancing lesions during the 18-month treatment period. After 18 months, the levels of interleukin (IL)-4, IL-10, transforming growth factor-β and serum ferric reducing antioxidant power in the atorvastatin treatment group were significantly higher than the control group. Levels of IL-17, TNF-α and lymphocyte proliferation in the atorvastatin treatment group were significantly lower than the control group. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1788745151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4055715641</sourcerecordid><originalsourceid>FETCH-proquest_journals_17887451513</originalsourceid><addsrcrecordid>eNqNi8sKwjAURIMoWB__cMF1ISG26VZFUdCVXRREStBbbIlJTW79frvoBwgDc2DOjFgklEximapiPLCQmZyyWQgN52nKBY_Y-WQJfYXeWbhtkfQ9Fhq0fcKGnP_qQJpqC33ohZB71PRGS-AquHSG6tYgXB-m_4c6LNik0ibgcug5Wx32-e4Yt959OgxUNq7ztp9KobJMrRORCPmf9QMzfD6Z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1788745151</pqid></control><display><type>article</type><title>Interferon [Beta]-1a and Atorvastatin in the Treatment of Multiple Sclerosis</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ghasami, Keyvan ; Faraji, Fardin ; Fazeli, Masoud ; Ghazavi, Ali ; Mosayebi, Ghasem</creator><creatorcontrib>Ghasami, Keyvan ; Faraji, Fardin ; Fazeli, Masoud ; Ghazavi, Ali ; Mosayebi, Ghasem</creatorcontrib><description>This paper aims to evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled clinical trial. Multiple sclerosis patients were randomized independently, in a double blind design, into one of two treatment groups. Control group (n=45) received 30 μg/week interferon β-1a via intra-muscular injection. Atorvastatin-treated group (n=50) received interferon β-1a similar to control group in addition to atorvastatin (40 mg/day) for 18-months. All clinical and immunological variables were measured at the baseline and at the end of the study. There was no significant difference between the two groups in the expanded disability status scale scores and the number of gadolinium-enhancing lesions during the 18-month treatment period. After 18 months, the levels of interleukin (IL)-4, IL-10, transforming growth factor-β and serum ferric reducing antioxidant power in the atorvastatin treatment group were significantly higher than the control group. Levels of IL-17, TNF-α and lymphocyte proliferation in the atorvastatin treatment group were significantly lower than the control group.</description><identifier>ISSN: 1735-1383</identifier><identifier>EISSN: 1735-367X</identifier><language>eng</language><publisher>Shiraz: Shiraz Institute for Cancer Research</publisher><subject>Antigens ; Clinical trials ; Cytokines ; Disease ; Drug dosages ; Immunology ; Multiple sclerosis ; NMR ; Nuclear magnetic resonance ; Studies ; Substance abuse treatment ; Tumor necrosis factor-TNF ; Values</subject><ispartof>Iranian journal of immunology, 2016-03, Vol.13 (1), p.16</ispartof><rights>Copyright Shiraz Institute for Cancer Research Mar 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Ghasami, Keyvan</creatorcontrib><creatorcontrib>Faraji, Fardin</creatorcontrib><creatorcontrib>Fazeli, Masoud</creatorcontrib><creatorcontrib>Ghazavi, Ali</creatorcontrib><creatorcontrib>Mosayebi, Ghasem</creatorcontrib><title>Interferon [Beta]-1a and Atorvastatin in the Treatment of Multiple Sclerosis</title><title>Iranian journal of immunology</title><description>This paper aims to evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled clinical trial. Multiple sclerosis patients were randomized independently, in a double blind design, into one of two treatment groups. Control group (n=45) received 30 μg/week interferon β-1a via intra-muscular injection. Atorvastatin-treated group (n=50) received interferon β-1a similar to control group in addition to atorvastatin (40 mg/day) for 18-months. All clinical and immunological variables were measured at the baseline and at the end of the study. There was no significant difference between the two groups in the expanded disability status scale scores and the number of gadolinium-enhancing lesions during the 18-month treatment period. After 18 months, the levels of interleukin (IL)-4, IL-10, transforming growth factor-β and serum ferric reducing antioxidant power in the atorvastatin treatment group were significantly higher than the control group. Levels of IL-17, TNF-α and lymphocyte proliferation in the atorvastatin treatment group were significantly lower than the control group.</description><subject>Antigens</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Immunology</subject><subject>Multiple sclerosis</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Studies</subject><subject>Substance abuse treatment</subject><subject>Tumor necrosis factor-TNF</subject><subject>Values</subject><issn>1735-1383</issn><issn>1735-367X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNi8sKwjAURIMoWB__cMF1ISG26VZFUdCVXRREStBbbIlJTW79frvoBwgDc2DOjFgklEximapiPLCQmZyyWQgN52nKBY_Y-WQJfYXeWbhtkfQ9Fhq0fcKGnP_qQJpqC33ohZB71PRGS-AquHSG6tYgXB-m_4c6LNik0ibgcug5Wx32-e4Yt959OgxUNq7ztp9KobJMrRORCPmf9QMzfD6Z</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Ghasami, Keyvan</creator><creator>Faraji, Fardin</creator><creator>Fazeli, Masoud</creator><creator>Ghazavi, Ali</creator><creator>Mosayebi, Ghasem</creator><general>Shiraz Institute for Cancer Research</general><scope>3V.</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20160301</creationdate><title>Interferon [Beta]-1a and Atorvastatin in the Treatment of Multiple Sclerosis</title><author>Ghasami, Keyvan ; Faraji, Fardin ; Fazeli, Masoud ; Ghazavi, Ali ; Mosayebi, Ghasem</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_17887451513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antigens</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Immunology</topic><topic>Multiple sclerosis</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Studies</topic><topic>Substance abuse treatment</topic><topic>Tumor necrosis factor-TNF</topic><topic>Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghasami, Keyvan</creatorcontrib><creatorcontrib>Faraji, Fardin</creatorcontrib><creatorcontrib>Fazeli, Masoud</creatorcontrib><creatorcontrib>Ghazavi, Ali</creatorcontrib><creatorcontrib>Mosayebi, Ghasem</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Iranian journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghasami, Keyvan</au><au>Faraji, Fardin</au><au>Fazeli, Masoud</au><au>Ghazavi, Ali</au><au>Mosayebi, Ghasem</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interferon [Beta]-1a and Atorvastatin in the Treatment of Multiple Sclerosis</atitle><jtitle>Iranian journal of immunology</jtitle><date>2016-03-01</date><risdate>2016</risdate><volume>13</volume><issue>1</issue><spage>16</spage><pages>16-</pages><issn>1735-1383</issn><eissn>1735-367X</eissn><abstract>This paper aims to evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled clinical trial. Multiple sclerosis patients were randomized independently, in a double blind design, into one of two treatment groups. Control group (n=45) received 30 μg/week interferon β-1a via intra-muscular injection. Atorvastatin-treated group (n=50) received interferon β-1a similar to control group in addition to atorvastatin (40 mg/day) for 18-months. All clinical and immunological variables were measured at the baseline and at the end of the study. There was no significant difference between the two groups in the expanded disability status scale scores and the number of gadolinium-enhancing lesions during the 18-month treatment period. After 18 months, the levels of interleukin (IL)-4, IL-10, transforming growth factor-β and serum ferric reducing antioxidant power in the atorvastatin treatment group were significantly higher than the control group. Levels of IL-17, TNF-α and lymphocyte proliferation in the atorvastatin treatment group were significantly lower than the control group.</abstract><cop>Shiraz</cop><pub>Shiraz Institute for Cancer Research</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1735-1383 |
| ispartof | Iranian journal of immunology, 2016-03, Vol.13 (1), p.16 |
| issn | 1735-1383 1735-367X |
| language | eng |
| recordid | cdi_proquest_journals_1788745151 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Antigens Clinical trials Cytokines Disease Drug dosages Immunology Multiple sclerosis NMR Nuclear magnetic resonance Studies Substance abuse treatment Tumor necrosis factor-TNF Values |
| title | Interferon [Beta]-1a and Atorvastatin in the Treatment of Multiple Sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T02%3A28%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interferon%20%5BBeta%5D-1a%20and%20Atorvastatin%20in%20the%20Treatment%20of%20Multiple%20Sclerosis&rft.jtitle=Iranian%20journal%20of%20immunology&rft.au=Ghasami,%20Keyvan&rft.date=2016-03-01&rft.volume=13&rft.issue=1&rft.spage=16&rft.pages=16-&rft.issn=1735-1383&rft.eissn=1735-367X&rft_id=info:doi/&rft_dat=%3Cproquest%3E4055715641%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1788745151&rft_id=info:pmid/&rfr_iscdi=true |